Author: it
Jul2016
Ariana Pharma joins the Healthcare Data Institute
Ariana is pleased to announce that the company has joined the Healthcare Data Institute. The Healthcare Data Institute is the first international think tank dedicated to Big Data in the health sector. An Orange Healthcare initiative, the Healthcare Data Institute was launched in partnership with other companies representative of the Big Data health ecosystem: […]
Jul2016
Pharma Boardroom interview with Mohammad Afshar
Interview with Mohammad Afshar – CEO, Ariana Pharma, France, 12 July 2016 Mohammad Afshar, CEO of Ariana Pharma, shares his insights on the importance of decision support tools, big data’s impact on the healthcare industry, and the need to translate this data into the production of real products. He also discusses the challenges he faced […]
Jun2016
Is the Efficacy of Milnacipran in Fibromyalgia Predictable? A Data-Mining Analysis of Baseline and Outcome Variables
Ariana Pharma and Laboratoires Pierre Fabre have recently published the results of a clinical data mining study using KEM to identify the best responder subgroups for Milnacipran in fibromyalgia. “Is the Efficacy of Milnacipran in Fibromyalgia Predictable? A Data-Mining Analysis of Baseline and Outcome Variables”, Lilia Abtroun, PhD, Pierre Bunouf, PhD, Roger M Gendreau, MD, […]
Jun2016
WIN 2016 Symposium (Paris | June 27-28)
The WIN 2016 Symposium is the place to be to learn about the latest in cancer research by world class presenters. Come and meet the Ariana team of Dr Mohammad Afshar, Dr Guergova-Kuras, Dr Morley and Dr Vaucouleur.
May2016
Ariana Science Day (Paris | May 9)
Ariana hosted their regular Science Day this week – a 1-day symposium in Paris on advances in machine learning and artificial intelligence, chaired by Dr Jean Sallantin, Director of Research at the CNRS LIRMM (Laboratoire d’Informatique, de Robotique et de Micro-électronique de Montpellier) and Scientific Advisor to Ariana. As ever, this was a stimulating […]
Apr2016
NoFinishLine Paris 2016 (Paris | April 13)
The Ariana Running Team are pleased to participate in the popular NoFinishLine Paris 2016 charitable fun run event in support of sick and homeless children. Ariana Running Team at NoFinishLine Paris 2016 (Left to right): Sébastien Vaucouleur, Isabelle Chaduteau, Dan Manak, Mohammad Afshar, Yannic Tognetti, Frédéric Parmentier (11254), David Morley, Vincent Récamier, Julie Miralves, […]
Jun2015
WIN 2015 Symposium (Paris | 29-30 June)
Dr Mohammad Afshar (Founder and CEO) is presenting our Onco KEM® platform at WIN 2015 on 29 June. Dr. Mariana Guergova-Kuras (CTO) and Dr David Morley (VP Computational Technology) will also be attending the symposium for a fascinating two days of cutting-edge presentations and discussions with global key opinion leaders in cancer research and precision cancer […]
Jun2015
Ariana® Pharma teams together with SIB Swiss Institute of Bioinformatics to discover novel biomarkers for gastric cancer
Leader in clinical big data analytics collaborates with world-class bioinformatics provider in GastricGlycoExplorer consortiumPartnership to develop early detection tools for one of the deadliest cancers Links: Download English PDF | Download French PDF Paris, France, Cambridge, Massachusetts USA, and Geneva, Switzerland, 1 June 2015 – Ariana Pharma, developer of innovative clinical data analysis and diagnostic […]
Jan2015
Nabsys and Ariana Pharma Collaborate to Identify DNA Structural Variants Linked to Targeted Cancers
Nabsys will collaborate with Ariana Pharmaceuticals to identify structural variations related to breast and prostate cancer and how they affect clinical outcome of patients. Links: Download English PDF Providence, Rhode Island, USA, and Paris, FRANCE – January 12th , 2015 – Nabsys, Inc., a life sciences company pioneering semiconductor-based tools for human genomic analysis in […]
Dec2014
Onco KEM(R) platform for personalized cancer treatment selection
Ariana Pharma releases a video to illustrate its innovative Onco KEM® platform for personalized cancer treatment selection. Onco KEM® intends to accelerate the translation of personalized medicine discoveries into widely available new standards of care for all cancer patients, leading to significantly improved clinical outcomes and a higher quality of life for cancer patients. […]